FDA Drug Safety Information for December 20, 2024

Dec 202024
 

Date Brand Name(s) Description Type Reason Company  12/20/2024 Par Pharmaceutical Adrenalin® Chloride Solution (EPINEPHrine nasal solution, USP) Drugs Product is an unapproved drug. Endo, Inc.

Updated Drug Shortage Information for December 19, 2024

Dec 192024
 

Shortage Updates December 19, 2024 Bupivacaine Hydrochloride Injection (Currently In Shortage) Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently In Shortage) Dextrose Monohydrate 25% Injection (Resolved) Dextrose Monohydrate 50% Injection (Currently

Updated Drug Shortage Information for December 10, 2024

Dec 102024
 

New Shortages December 10, 2024 Adalimumab-Adbm Injection (Discontinuation)   December 9, 2024 Lodoxamide Tromethamine Solution (Discontinuation) Tiagabine Hydrochloride Tablet (Discontinuation) Tigecycline Injection (Discontinuation)   December 6, 2024 Sodium Chloride

Updated Drug Shortage Information for December 5, 2024

Dec 052024
 

New Shortages December 5, 2024 Clindamycin Hydrochloride Capsule (Discontinuation) Cyclosporine Oral Solution (Discontinuation) Desmopressin Acetate Injection (Discontinuation) Digoxin Tablet (Discontinuation) Edaravone Injection (Discontinuation) Imatinib Mesylate Tablet (Discontinuation) Pantoprazole Sodium Injection (Discontinuation)

FDA Novel Drug Approvals – November 2024

Dec 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Iomervu iomeprol 11/27/2024 For use as a radiographic contrast

 Older Entries  Newer Entries